参考文献/References:
[1] 叶琇锦,钱文斌.滤泡性淋巴瘤预后和分层治疗策略[J].中国实用内科杂志,2015,35(2):99-101.[2] 潘毅,孟斌,付凯,等.98 例滤泡性淋巴瘤组织学及遗传学的初步研究[J].中国肿瘤临床,2011,18:1075-1080.[3] Swerdlow S H,Campo E,Pileri SA,et al.The 2016 revisionof the World Health Organization classification of lymphoidneoplasms[J].Blood.2016,127(20):2375-2390.[4] Wahlin B E,Yri O E,Kimby E,et al.Clinical significance ofthe WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times[J].British Journal of Haematology,2011,156(2):225-233.[5] 许彭鹏,余栋,钱樱,等.两种滤泡性淋巴瘤国际预后指数对利妥昔单抗联合化疗治疗滤泡性淋巴瘤的预后意义[J].白血病·淋巴瘤,2013(12):720-723.[6] U Dührsen,Broszeitluft S,Dieing A,et al.Rituximabmaintenance therapy of follicular lymphoma in clinicalpractice[J].Cancer Medicine,2018,7(7):2903-2912.[7] Barr P M.Rituximab maintenance in follicular lymphoma[J].Clin Adv Hematol Oncol,2015,13(3):158-161.[8] 陈紫桂.滤泡性淋巴瘤的发病机制与治疗的研究进展[J].贵州医药,2016,40(1):94-97.[9] 杜晓艳,王晶,克晓燕.滤泡性淋巴瘤的靶向药物研究进展[J].现代肿瘤医学,2017,25(20):3358-3360.[10] 杜晓艳,胡凯,赵伟,等.94 例滤泡性淋巴瘤患者的临床特征及预后因素分析[J].中国实验血液学杂志,2018,26(3):756-764.[11] Cartron G,Watier H,Golay J,et al.From the bench to thebedside:ways to improve rituximab efficacy[J].Blood 2004;104(9):2635-2642.[12] 别俊,胡欣,李爽.利妥昔单抗联合 CHOP 方案治疗滤泡性淋巴瘤对免疫功能及补体的影响[J].现代中西医结合杂志,2014,23(33):3698-3700.[13] Winter M C,Hancock B W.Ten years of rituximab inNHL[J].Expert Opinion on Drug Safety,2009,8(2):223-235.[14] 王楠,赵维莅.基于分子异质性的滤泡性淋巴瘤诊治进展[J].临床血液学杂志,2018,31(3):337-342.[15] 吴剑秋,宋永平,苏丽萍,等.滤泡性淋巴瘤患者接受利妥昔单抗为基础方案一线治疗的现状研究[J].中华血液杂志,2014,35(5):456-458.[16] Erblich T,Montoto S.Treating relapsed follicular lymphoma[J].Expert Review of Hematology,2018,2018,11(5):403-410.[17] Sehn L H,Chua N,Mayer J,et al.Obinutuzumab plusbendamustine versus bendamustine monotherapy in patientswith rituximab-refractory indolent non-Hodgkin lymphoma(GADOLIN):a randomised,controlled,open-label,multicentre,phase 3 trial [J].Lancet Oncology,2016,17(8):1081-1093.[18] Karmali R,Kimby E,Ghielmini M,et al.Rituximab:a benchmarkin the development of chemotherapy-free treatment strategiesfor follicular lymphomas [J].Annals of Oncology OfficialJournal of the European Society for Medical Oncology,2018,29(2):332-340.[19] Rodríguez Villa,S,Ruiz Rodríguez,M.J,Vargas Pabón,M.Intralesional rituximab in primary conjunctival follicularlymphoma relapsed[J].Archivos de la Sociedad Espa?ola deOftalmología (English Edition) (English Edition).2017,92(7):326-329.[20] Tuscano J M,Dutia M,Chee K,et al.Lenalidomide plusrituximab can produce durable clinical responses in patientswith relapsed or refractory,indolent non-Hodgkin lymphoma[J].British Journal of Haematology,2014,165(3):375-381.[21] David B,Vit P,Andrea J,et al.The influence of maintenancetherapy of rituximab on the survival of elderly patients withfollicular lymphoma.A retrospective analysis from thedatabase of the Czech Lymphoma Study Group[J].Leukemia Research,2018,73:29-38.[22] Morschhauser F,Fowler N H,Feugier P,et al.Rituximab plusLenalidomide in advanced untreated follicular lymphoma.[J].The New England Journal of Medicine.2018,379(10):934-947.[23] 许彭鹏,钱樱,陈秋生,等.滤泡性淋巴瘤国际预后指数 2 在利妥昔单克隆抗体维持治疗滤泡性淋巴瘤患者中的预后意义[J].中国实验血液学杂志,2017,2:426-430.[24] Salles G A,Seymour J F,Feugier P,et al.Updated 6 yearfollow-up of the PRIMA study confirms the benefit of2-year rituximab maintenance in follicular lymphomapatients responding to frontline immunochemotherapy[J].Blood,2010,116(21):746-746.[25] Vidal L,Gafter-Gvili A,Salles G,et al.Rituximab maintenanceimproves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis [J].European Journal ofCancer,2017,76:216-225.[26] 陈晓晨.吴德沛.利妥昔单抗时代滤泡性淋巴瘤移植治疗的现状及前景[J].白血病·淋巴瘤,2013(6):335-338.